Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer

Authors: Zhengjun Yang, Bin Zhang, Bowen Liu, Yegong Xie, Xuchen Cao

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

The purpose of this study was to investigate the prognostic value of Runx2 and Snail expression in breast cancer. The expression of Runx2 and Snail in clinical specimens from 125 breast cancer patients was detected by immunohistochemistry. The results showed there is a link between Runx2 and Snail expression at protein levels (p = 0.007). The Kaplan-Meier survival analysis showed that Runx2 or Snail expression was correlated with shortened disease-free survival (DFS) (p = 0.002, p = 0.004, respectively) and overall survival (OS) (p = 0.002, p = 0.009, respectively). In addition, Runx2-positive/Snail-positive patients had the worst DFS and OS (p = 0.001, p < 0.001, respectively). In multivariate survival analysis, Runx2, Snail, and combined Runx2/Snail were still remained as independent prognostic factors for DFS (p = 0.020, p = 0.013, and p = 0.001, respectively) and OS (p = 0.027, p = 0.030 and p = 0.005, respectively). These results suggest that a combined Runx2/Snail expression could be used as a new significant prognostic biomarker for patients with breast cancer.
Appendix
Available only for authorised users
Literature
1.
Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2:61.PubMedPubMedCentral
2.
Orecchia R, Leonardi MC, Maisonneuve P, Morra A, Lazzari R, Cattani F, et al. Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience. Transl Cancer Res. 2014;3(1):59–64.
3.
Zhang M, Li Z, Zhang X, Chang Y. Cancer stem cells as a potential therapeutic target in breast cancer. Stem Cell Investig. 2014;1:14.PubMedPubMedCentral
4.
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(S1):S2–8.PubMedPubMedCentral
5.
Tan XF, Xia F. Long-term fatigue state in postoperative patients with breast cancer. Chin J Cancer Res. 2014;26(1):12–6.PubMedPubMedCentral
6.
Williams NR, Pigott KH, Brew-Graves C, Keshtgar MR. Intraoperative radiotherapy for breast cancer. Gland Surg. 2014;3(2):109–19.PubMedPubMedCentral
7.
Doisneau-Sixou S, Harbeck N. From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer. Chin Clin Oncol. 2014;3(2):16.PubMed
8.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755–64.CrossRefPubMed
9.
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–54.CrossRefPubMed
10.
Wai PY, Mi Z, Gao C, Guo H, Marroquin C, Kuo PC. Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem. 2006;281:18973–82.CrossRefPubMed
11.
Endo T, Ohta K, Kobayashi T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab. 2008;93:2409–12.CrossRefPubMed
12.
Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci. 2010;101:2670–5.CrossRefPubMed
13.
Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.CrossRefPubMed
14.
Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. Snai1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007;67:11721–31.CrossRefPubMed
15.
van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, et al. Co-expression of snail and twist determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat. 2012;133:49–59.CrossRefPubMed
16.
Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, et al. Transcription factor runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Investig J Tech Methods Pathol. 2012;92:1181–90.CrossRef
17.
Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by runx2 and estrogen signaling: the role of SNAi2. Breast Cancer Res: BCR. 2011;13:R127.CrossRefPubMedPubMedCentral
18.
Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by runx2/snail signaling pathway. J Biol Chem. 2011;286:37335–46.CrossRefPubMedPubMedCentral
19.
Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007;211:532–40.CrossRefPubMed
20.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed
21.
Li H, Zhou RJ, Zhang GQ, Xu JP. Clinical significance of runx2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1807–12.CrossRef
22.
Sase T, Suzuki T, Miura K, Shiiba K, Sato I, Nakamura Y, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer. 2012;131:2284–93.CrossRefPubMed
23.
Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, et al. Positive association between nuclear runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer. 2009;45:2239–48.CrossRefPubMedPubMedCentral
24.
McDonald L, Ferrari N, Terry A, Bell M, Mohammed ZM, Orange C, et al. Runx2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of runx2 perturbs differentiation in the mouse mammary gland. Dis Models Mech. 2014;7:525–34.CrossRef
25.
Park SJ, Jung SH, Jogeswar G, Ryoo HM, Yook JI, Choi HS, et al. The transcription factor snail regulates osteogenic differentiation by repressing runx2 expression. Bone. 2010;46:1498–507.CrossRefPubMed
26.
Osborne CK, Yochmowitz MG, Knight 3rd WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884–8.CrossRefPubMed
27.
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, et al. Runx3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512–20.CrossRefPubMed
28.
Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, et al. Modulation of runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology. 2008;149:5984–95.CrossRefPubMedPubMedCentral
29.
Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of n-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779–90.CrossRefPubMedPubMedCentral
Metadata
Title
Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer
Authors
Zhengjun Yang
Bin Zhang
Bowen Liu
Yegong Xie
Xuchen Cao
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3101-3

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK

Research Article

SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients

Research Article

Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells

Research Article

Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway

Research Article

Significance of Trask protein interactions in brain metastatic cohorts of lung cancers

Review

Long non-coding RNA functions in lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits